🔎 Trials Near Me

Domov › Akútna myeloidná leukémia › Ohio

Klinické štúdie Akútna myeloidná leukémia v štáte Ohio

57 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v štáte Ohio.

Mestá v štáte Ohio

Oficiálny text štúdie (anglicky)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 2
Vek 60 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • a 44 ďalších
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Prebieha náborObservačná štúdia
Vek 0 až 38 · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Case Western Reserve University, Cleveland
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Gabrail Cancer Center, Canton
  • Miami Valley Hospital South, Centerville
  • Oncology Hematology Care, Cincinnati
  • a 2 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Case Western Reserve University, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05564390

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT03874052

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Prebieha náborFáza 1
Do veku 21 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Case Western Reserve University, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Case Western Reserve University, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Rainbow Babies and Childrens Hospital, Cleveland
  • a 4 ďalších
Prebieha náborFáza 3
6 Months – 21 Years · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Ohio State University, Columbus
Prebieha náborFáza 1/2
30 Days · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT04065399

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT06904482

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT03471260

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

  • Ohio State University, The James Comprehensive Cancer, Columbus
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06846606

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • The Ohio Sate University, Columbus
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT06969430

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 1/2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT04049539

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Rainbow Babies and Childrens Hospital, Cleveland
  • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
Prebieha náborFáza 3
Vek 1 až 25 · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07022678

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • University of Cincinnati, Cincinnati
  • OhioHealth Research Institute, Columbus
  • Taylor Cancer Research Center, Maumee
Prebieha náborObservačná štúdia
Vek 0 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Cincinnati OH-CINCY, Cincinnati
  • US-Colombus OH-OSU, Columbus
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Cincinnati OH-CINCY, Cincinnati
  • US-Colombus OH-OSU, Columbus
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07223814

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 8. 2026 · NCT06930352

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

  • Cleveland Clinic, Cleveland
  • Ohio State University, Columbus
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT06533761

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
  • University of Cincinnati Cancer Center-West Chester, West Chester
Prebieha náborFáza 1
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Rainbow Babies and Childrens Hospital, Cleveland
  • a 3 ďalších
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Nationwide Children's Hospital, Columbus
Prebieha náborFáza 3
29 Days – 21 Years · Všetky pohlavia · Aktualizované 24. 8. 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Ohio State University, Columbus
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • UH Seidman Cancer Center, Cleveland
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT06001788

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

  • University Hospitals Cleveland Medical Center, Cleveland
Prebieha náborFáza 2/3
Vek 18 až 80 · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT06788756

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Prebieha náborFáza 1
Vek 1 až 30 · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT06177067

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • University of Cincinnati Medical Center (University Hospital), Cincinnati
  • The Ohio State University Comprehensive Cancer Center (OSUCCC), Cleveland
Prebieha náborFáza 3
Vek 18 až 75 · Všetky pohlavia · Aktualizované 17. 7. 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Childrens Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital, Cincinnati
  • University Hospitals Case Medical Center, Cleveland
  • a 3 ďalších
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT01351545

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 6. 2026 · NCT05401097

Ivosidenib as Post-HSCT Maintenance for AML

  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 18. 6. 2026 · NCT06707493

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

  • Case Western Reserve University, Cleveland
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 12. 6. 2026 · NCT05834244

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

  • Ohio State University Comprehensive Cancer Center, Columbus
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 5. 2026 · NCT06222580

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
  • The Ohio State University, Columbus
Prebieha náborFáza 1
Vek 13 a viac · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 4. 2026 · NCT04256317

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
  • University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 27. 4. 2026 · NCT06129734

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • Cincinnati Children's Hospital, Cincinnati
Prebieha náborFáza 1
Do veku 21 · Všetky pohlavia · Aktualizované 22. 4. 2026 · NCT05101551

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.